Lifeng Yin

Mr. Lifeng Yin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
ABAjay H. Bansode
Ajay H. Bansode
LYLifeng Yin
Lifeng Yin
NDNing Deng
Ning Deng
MAMahmoud Afrasi
Mahmoud Afrasi
YZYiyi Zhu
Yiyi Zhu
MPMarvin Parasram
Marvin Parasram

21 January 2025 in Angewandte Chemie
Verified
Journal Article
Closed access
ABAjay H. Bansode
Ajay H. Bansode
LYLifeng Yin
Lifeng Yin
NDNing Deng
Ning Deng
MAMahmoud Afrasi
Mahmoud Afrasi
YZYiyi Zhu
Yiyi Zhu
MPMarvin Parasram
Marvin Parasram

30 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CZChunlian Zhong
Chunlian Zhong
LYLifeng Yin
Lifeng Yin
MHMichael Hung
Michael Hung
Shanshan YaoShanshan Yao
Shanshan Yao
MTMenghuan Tang
Menghuan Tang
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
Urinary cancers present a severe clinical challenge due to high recurrence rates. Standard intravesical therapies suffer from limited efficacy because of the urinary tract’s robust physiological defenses, namely, the dynamic washout effect during voiding and highly restrictive urothelial barriers, such as the anti-adhesive glycosaminoglycan layer and intercellular tight junctions. This review aims to explore how biomimetic engineering can overcome these obstacles by transitioning drug delivery from passive carriers to active, nature-inspired systems. We conducted a comprehensive review of the recent literature focusing on biomimetic strategies for intravesical drug delivery and urinary cancer theranostics. The analyzed approaches are categorized into chemical biomimicry (such as adhesion and camouflage) and structural/functional biomimicry (including adaptive devices and microrobots). Biomimetic strategies significantly enhance targeted drug retention and tissue penetration. Chemical biomimicry, utilizing mussel-inspired catechol chemistry and cell membrane camouflage, effectively bypasses the urothelial anti-adhesive defenses and reduces the immune clearance. Structural and functional biomimicry, such as naturally derived carriers and actively propelled magnetic or biohybrid microrobots, enables the precise spatial localization and controlled payload release in dynamic fluid environments. Furthermore, lab-on-a-chip technologies and patient-derived organoids (PDOs) offer scalable platforms for screening cargo-specific efficacies and tailoring treatments, providing a crucial bridge to personalized precision medicine. Integrating nature-inspired designs with advanced nanotechnologies provides a highly promising pathway with which to overcome the mechanical and biological barriers of the urinary tract. These biomimetic innovations hold the potential to shift the therapeutic paradigm for urinary oncology, paving the way for more efficient, targeted, and personalized precision medicine.

9 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
ABAjay Bansode
Ajay Bansode
LYLifeng Yin
Lifeng Yin
NDNing Deng
Ning Deng
MAMahmoud Afrasi
Mahmoud Afrasi
YZYiyi Zhu
Yiyi Zhu
MPMarvin Parasram
Marvin Parasram
Herein, we report a Lewis acid-mediated ring expansion of donor-acceptor cyclopropanes (DACs) to substituted azetidines via nucleophilic nitrogen atom transfer from readily accessible iminoiodinane. This protocol operates under mild, transition-metal-free conditions, and showcases excellent chemoselectivity, along with broad functional group tolerance. We report for the first time that challenging alkyl donor-acceptor cyclopropanes can undergo ring expansion leading to aliphatic azetidines without relying on external oxidants or precious transition-metal catalysts. Mechanistically, the coordination of a magnesium (Mg)-Lewis acid to the DAC promotes nucleophilic ring opening with a putative Mg-amide species generated from the iminoiodinane under the reaction conditions to furnish the azetidine products.